Literature DB >> 3085989

Absorption of oral diphosphonate in normal subjects.

I Fogelman, L Smith, R Mazess, M A Wilson, J A Bevan.   

Abstract

Absorption of the diphosphonate etidronate (HEDP) was measured in 20 volunteer subjects at two centres (Glasgow and Madison) using a new method based on simultaneous administration of HEDP and intravenous 99mTc-HEDP (Osteoscan). The mean absorption of HEDP in fasting subjects in Glasgow was 3.5% (range 1-8.9%) and in Madison 1.5% (0.7-2.8%) (P less than 0.035). In four subjects studies were repeated with good agreement between results (mean 3.9 cf. 3.5%). Six subjects had studies repeated when drug was ingested with food and in all cases absorption was effectively reduced to zero. We conclude that absorption of HEDP is significantly higher in normal subjects in Glasgow than in Madison. This may be of importance with regard to the finding of histological osteomalacia and fracture associated with HEDP use in Glasgow.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085989     DOI: 10.1111/j.1365-2265.1986.tb03254.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  29 in total

1.  The effect of dosing regimen on the pharmacokinetics of risedronate.

Authors:  D Y Mitchell; M A Heise; K A Pallone; M E Clay; J D Nesbitt; D A Russell; C W Melson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 2.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Improvement in Discomfort and Decreased Blood Flow Associated with Severe Arterial Wall Calcification following Etidronic Acid.

Authors:  M Mizuno; N Kashima; K Kato; A Ito; S Matsuo
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

4.  The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.

Authors:  P T Daley-Yates; D J Dodwell; M Pongchaidecha; R E Coleman; A Howell
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

5.  Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study.

Authors:  Daniel T Grima; Alexandra Papaioannou; Parisa Airia; George Ioannidis; Jonathan D Adachi
Journal:  BMC Musculoskelet Disord       Date:  2010-04-14       Impact factor: 2.362

Review 6.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 7.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

Review 8.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 9.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.